These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry. Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848 [TBL] [Abstract][Full Text] [Related]
19. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer. Rzazade R; Pham NT; Turna M; Canoglu MD; Kucukmorkoc E; Berberoglu K; Caglar HB J Radiosurg SBRT; 2022; 8(4):275-282. PubMed ID: 37416328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]